Results of the Combined General Shareholders’ Meeting of June 30, 2021
01/07/2021 – AB Science announces today the results of the Combined General Shareholders’ Meeting of June 30, 2021
01/07/2021 – AB Science announces today the results of the Combined General Shareholders’ Meeting of June 30, 2021
28/06/2021 – AB Science announced today that it has signed an agreement with historical shareholders to implement a joint strategy to increase the value of masitinib
10/06/2021 – AB Science today announced that results from masitinib study AB12005 in pancreatic cancer have been presented at the 2021 ASCO Annual Meeting
08/06/2021 – AB Science is providing a summary of the live webcast held on June 3, 2021 following the voluntary hold in the clinical studies of masitinib
08/06/2021 : Presentation of the webcast that was held following the voluntary hold of clinical studies with masitinib
02/06/2021 – AB Science will host a live webcast on June 3, 2021 to provide details on the decision to suspend voluntarily the clinical studies with masitinib
01/06/2021 – AB Science announced today that it has taken the decision to suspend inclusions and treatment initiation in its clinical studies with masitinib worldwide
26/05/2021 – AB Science communicated the results from Phase 3 study evaluating masitinib in prostate cancer during the webcast that was held on May 25, 2021
25/05/2021 – Presentation of the webcast held on May 25, 2021 on masitinib in prostate Cancer Download PDF
21/05/2021 – AB Science will host a live webcast on May 25, 2021 to discuss recently reported results from the Phase 2B/3 masitinib trial in prostate cancer